{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:05:28Z","timestamp":1761948328446,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00520-018-4133-1","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T05:31:22Z","timestamp":1520400682000},"page":"2833-2841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data"],"prefix":"10.1007","volume":"26","author":[{"given":"Christopher","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohini K.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Cyprien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Liede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"4133_CR1","unstructured":"National Cancer Institute (2016) SEER Cancer Stat Facts: myeloma. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html . Accessed March 28, 2017"},{"key":"4133_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"4133_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/joim.12590","volume":"281","author":"O Landgren","year":"2017","unstructured":"Landgren O, Iskander K (2017) Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med 281:365\u2013382","journal-title":"J Intern Med"},{"key":"4133_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1586\/ehm.09.36","volume":"2","author":"D Christoulas","year":"2009","unstructured":"Christoulas D, Terpos E, Dimopoulos MA (2009) Pathogenesis and management of myeloma bone disease. Expert Rev Hematol 2:385\u2013398","journal-title":"Expert Rev Hematol"},{"key":"4133_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21\u201333","journal-title":"Mayo Clin Proc"},{"key":"4133_CR6","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102:1064\u20131069","journal-title":"Blood"},{"key":"4133_CR7","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","volume":"31","author":"E Terpos","year":"2013","unstructured":"Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, Garcia-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD (2013) International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 31:2347\u20132357","journal-title":"J Clin Oncol"},{"key":"4133_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334:488\u2013493","journal-title":"N Engl J Med"},{"key":"4133_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"JR Berenson","year":"1998","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593\u2013602","journal-title":"J Clin Oncol"},{"key":"4133_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558\u2013567","journal-title":"J Clin Oncol"},{"key":"4133_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.clml.2014.09.012","volume":"15","author":"N Grzasko","year":"2015","unstructured":"Grzasko N, Morawska M, Hus M (2015) Optimizing the treatment of patients with multiple myeloma and renal impairment. Clin Lymphoma Myeloma Leuk 15:187\u2013198","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4133_CR12","volume-title":"Full prescribing information","author":"Zometa\u00ae (zoledronic acid)","year":"2016","unstructured":"Zometa\u00ae (zoledronic acid) (2016) Full prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ"},{"key":"4133_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","volume":"65","author":"LM Knudsen","year":"2000","unstructured":"Knudsen LM, Hjorth M, Hippe E (2000) Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65:175\u2013181","journal-title":"Eur J Haematol"},{"key":"4133_CR14","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/cam4.1075","volume":"6","author":"Y Qian","year":"2017","unstructured":"Qian Y, Bhowmik D, Bond C, Wang S, Colman S, Hernandez RK, Cheng P, Intorcia M (2017) Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States. Cancer Med 6:1523\u20131530","journal-title":"Cancer Med"},{"key":"4133_CR15","unstructured":"National Kidney Foundation Inc (2002) KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Available at: http:\/\/www2kidneyorg\/professionals\/kdoqi\/guidelines_ckd\/p4_class_g1htm Accessed May 31, 2017"},{"key":"4133_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"key":"4133_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kumar S (2016) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 91:101\u2013119","journal-title":"Mayo Clin Proc"},{"key":"4133_CR18","unstructured":"National Comprehensive Cancer Network (2016) NCCN clinical practice guidelines in oncology (NCCN guidelines). Multiple myeloma. Version 3.2017. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf . Accessed March 29, 2017"},{"key":"4133_CR19","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood.V126.23.4501.4501","volume":"126","author":"Y Qian","year":"2015","unstructured":"Qian Y, Bhowmik D, Kachru N, Hernandez RK, Cheng P, Liede A (2015) Utilization patterns of bone-targeting agents among patients with multiple myeloma: analysis of real-world data [abstract]. Blood 126:4501","journal-title":"Blood"},{"key":"4133_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.clml.2017.02.007","volume":"17","author":"A Aviles","year":"2017","unstructured":"Aviles A, Nambo MJ, Huerta-Guzman J, Cleto S, Neri N (2017) Prolonged use of zoledronic acid (4 years) did not improve outcome in multiple myeloma patients. Clin Lymphoma Myeloma Leuk 17:207\u2013210","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4133_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317:48\u201358","journal-title":"JAMA"},{"key":"4133_CR22","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/leu.2008.131","volume":"22","author":"MA Dimopoulos","year":"2008","unstructured":"Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485\u20131493","journal-title":"Leukemia"},{"key":"4133_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/10428190601126602","volume":"48","author":"V Eleutherakis-Papaiakovou","year":"2007","unstructured":"Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, Michali E, Economopoulos T, Zervas K, Dimopoulos MA (2007) Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 48:337\u2013341","journal-title":"Leuk Lymphoma"},{"key":"4133_CR24","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1038\/bcj.2015.20","volume":"5","author":"WI Gonsalves","year":"2015","unstructured":"Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust S, Kyle RA, Gertz MA, Kumar SK (2015) Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 5:e296","journal-title":"Blood Cancer J"},{"key":"4133_CR25","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.2008.07002.x","volume":"144","author":"I Borrello","year":"2009","unstructured":"Borrello I (2009) Lenalidomide in renal insufficiency\u2014balancing the risks and benefits. Br J Haematol 144:446\u2013447 author reply 447-448","journal-title":"Br J Haematol"},{"key":"4133_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","volume":"84","author":"KA Kennel","year":"2009","unstructured":"Kennel KA, Drake MT (2009) Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 84:632\u2013637 quiz 638","journal-title":"Mayo Clin Proc"},{"key":"4133_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1089\/jpm.2009.9936","volume":"12","author":"EE Prommer","year":"2009","unstructured":"Prommer EE (2009) Toxicity of bisphosphonates. J Palliat Med 12:1061\u20131065","journal-title":"J Palliat Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4133-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T05:49:41Z","timestamp":1570859381000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4133-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4133"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4133-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"13 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Review Board of each oncology practice approved collaboration to contribute data to a large longitudinal EHR database; informed patient consent was waived per the US framework for retrospective noninterventional studies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CK, RKH, and AL are current employees of and own stock in Amgen Inc. CK was provided travel expense to ASH conference for presentation of this work. PCC is a former employee of Amgen Inc. and is currently employed by Kite Pharma Inc. LC has no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}